April 10, 2024 Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies The interaction between PD-1 and PD-L1 promotes tumor immune evasion, but immune checkpoint inhibitors can reinvigorate the immune system. However, most pa...
a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in...
在刚落幕的2024 AACR大会上,华东医药靶向 HPK1 PROTAC研究以POSTER展示,接下来更多创新成果即将亮相各大国际会议:口服HPK1小分子抑制剂HDM2004研究入选 2024-CIMT年会POSTER,迈华替尼Ⅲ期关键性临床研究(HDHY-MHTN-III-1907)阳性结果、口服PTPN2小分子抑制剂 HDM2010 研究分别入选2024 ASCO年会POSTER和摘要。 2024年...
Henlius’ phase 3 clinical study of its innovative anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) was published as poster presentation...